RPS6KA5
MOLECULAR TARGETribosomal protein S6 kinase A5
RPS6KA5 (ribosomal protein S6 kinase A5) is targeted by 31 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting RPS6KA5
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | alvocidib | 4.52 | 91 |
| 2 | ruxolitinib | 4.23 | 68 |
| 3 | bi 2536 | 4.01 | 54 |
| 4 | midostaurin | 3.85 | 46 |
| 5 | fasudil | 3.66 | 38 |
| 6 | nintedanib | 3.61 | 36 |
| 7 | bms 387032 | 3.47 | 31 |
| 8 | y 27632 | 3.47 | 31 |
| 9 | fedratinib | 3.40 | 29 |
| 10 | linifanib | 3.33 | 27 |
| 11 | sp 600125 | 3.22 | 24 |
| 12 | bisindolylmaleimide ix | 3.14 | 22 |
| 13 | dovitinib | 3.09 | 21 |
| 14 | at 9283 | 3.09 | 21 |
| 15 | lestaurtinib | 3.04 | 20 |
| 16 | pf 03758309 | 3.00 | 19 |
| 17 | ruboxistaurin | 2.94 | 18 |
| 18 | orantinib | 2.89 | 17 |
| 19 | r 406 | 2.83 | 16 |
| 20 | k 252a | 2.83 | 16 |
| 21 | hesperadin | 2.77 | 15 |
| 22 | pha 665752 | 2.71 | 14 |
| 23 | kw 2449 | 2.64 | 13 |
| 24 | gsk 690693 | 2.64 | 13 |
| 25 | ast 487 | 2.56 | 12 |
| 26 | su 014813 | 2.20 | 8 |
| 27 | enzastaurin | 2.08 | 7 |
| 28 | amg 900 | 2.08 | 7 |
| 29 | gsk 269962a | 2.08 | 7 |
| 30 | hydroxyfasudil [Supplementary Concept] | 1.10 | 2 |
| 31 | sp600125 | 0.69 | 1 |
About RPS6KA5 as a Drug Target
RPS6KA5 (ribosomal protein S6 kinase A5) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 31 compounds with documented RPS6KA5 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
RPS6KA5 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.